Identifying Effective Durations of Antibiotic Therapy for the Treatment of Carbapenem-resistant Enterobacterales Bloodstream Infections: A Multicenter Observational Study.
bacteremia
carbapenem-resistant Enterobacterales
ceftazidime-avibactam
meropenem
meropenem- vaborbactam
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
16 Aug 2023
16 Aug 2023
Historique:
received:
20
05
2023
revised:
13
07
2023
accepted:
11
08
2023
medline:
16
8
2023
pubmed:
16
8
2023
entrez:
16
8
2023
Statut:
aheadofprint
Résumé
In a propensity-score-weighted cohort of 183 adults with carbapenem-resistant Enterobacterales bacteremia at 24 United States hospitals, patients receiving short-courses of active therapy (7-10 days, median 9 days) experienced similar odds of recurrent bacteremia or death within 30 days as those receiving prolonged courses of active therapy (14-21 days, median 14 days).
Identifiants
pubmed: 37584360
pii: 7242975
doi: 10.1093/cid/ciad476
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.